Plain-English translation of NCT06323460 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating HPV-positive throat cancer that uses a simple blood test to guide treatment decisions. Instead of giving everyone the same amount of radiation therapy, doctors will measure tumor DNA in your blood at week 4. If the results show your cancer is responding well, you may receive a shorter course of radiation combined with chemotherapy. If the results show less response, you'll receive the standard longer course of treatment.
Standard radiation therapy for throat cancer can cause long-term side effects like difficulty swallowing. This trial hopes to spare patients these complications by personalizing treatment based on how well each person's cancer responds early on, rather than using a one-size-fits-all approach.
You likely qualify if…
You likely don't qualify if…
You will receive 4 weeks of daily radiation therapy (5 days a week) combined with chemotherapy given either weekly or every 3 weeks, depending on your doctor's judgment. At week 4, you'll have a blood test to measure tumor DNA levels. Based on those results, you'll either continue for 1 more week of treatment (if your cancer is responding well) or continue for 3 more weeks (if it's responding less well). Throughout the trial, you'll have PET/CT scans and regular blood draws to monitor your progress.
AI-generated summary from trial data · Aug 8, 2026 · Not medical advice
United States